(Press-News.org) The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.
The results show that treatment with dapagliflozin improved metabolic dysfunction-associated steatohepatitis (MASH) - a condition where excess fat accumulates in the liver, leading to inflammation - and liver fibrosis (a build up of scar tissue) compared with placebo.
MASH affects more than 5% of adults, more than 30% of individuals with diabetes or obesity, and can progress to cirrhosis in up to 25% of individuals.
Several studies have reported that SGLT-2 inhibitors can improve liver fat content, liver enzymes, and liver stiffness, but no trial has been carried out among patients with MASH.
To address this, researchers enrolled 154 adults (average age 35; 85% men) diagnosed with MASH after a liver biopsy at six medical centres in China from November 2018 to March 2023.
Almost half (45%) had type 2 diabetes, and almost all had liver fibrosis (33% stage 1, 45% stage 2, 19% stage 3).
After an initial screening biopsy, participants were randomly assigned to receive 10 mg of dapagliflozin or matching placebo once daily for 48 weeks and attended health education sessions twice a year.
Various factors including body weight, blood pressure, blood glucose, liver enzymes, physical activity, diet, insulin, and lipids were also assessed at enrollment and throughout the trial.
MASH improvement was defined as a decrease of at least 2 points in non-alcoholic fatty liver disease activity score (NAS) or a NAS of 3 points or less.
After an end of study biopsy at week 48, 53% (41 of 78) participants in the dapagliflozin group showed improvement in MASH without worsening of fibrosis (defined as no increase in fibrosis stage) compared with 30% (23 of 76) in the placebo group.
Resolution of MASH without worsening of fibrosis occurred in 23% (18 of 78) participants in the dapagliflozin group compared with 8% (6 of 76) in the placebo group.
Fibrosis improvement without worsening of MASH was also reported in 45% (35 of 78) participants in the dapagliflozin group compared with 20% (15 of 76) in the placebo group.
The percentage of participants who discontinued treatment because of adverse events was 1% (1 of 78) in the dapagliflozin group and 3% (2 of 76) in the placebo group.
The researchers acknowledge that the trial was conducted in a Chinese population, which limits its broader generalisability, and that female and older patients were under-represented. But they point out that results were consistent after further analyses, suggesting they are robust.
As such, they conclude: “Our findings indicate that dapagliflozin may affect key aspects of MASH by improving both steatohepatitis and fibrosis.” Large scale and long term trials are needed to further confirm these effects, they add.
The coming years are expected to be particularly exciting in the field of pharmacological treatment for MASH, say researchers from Argentina in a linked editorial.
As more drugs become available, therapeutic decisions will likely become increasingly tailored to individual patient profiles, they write. “Ideally, such treatments should provide cardiovascular benefit, have an established safety profile, and be accessible to broad and diverse patient populations,” they conclude.
[Ends]
END
Diabetes drug shows benefits for patients with liver disease
Results support the potential for dapagliflozin to benefit these patients
2025-06-04
ELSE PRESS RELEASES FROM THIS DATE:
P2Y12 drugs may be better than aspirin to prevent heart attack and stroke in patients with coronary artery disease
2025-06-04
Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds a study published by The BMJ today.
P2Y12 inhibitors are often given to patients alongside aspirin (“dual therapy”) after percutaneous coronary intervention (PCI) - a procedure to widen or unblock a coronary artery - to help prevent cardiovascular events including heart attack and stroke.
After several months, patients ...
Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
2025-06-04
(Vienna, Austria, Thursday 5 June 2025) New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile.1
IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure.² Many patients are unaware they have the condition until significant kidney ...
Landmark study reveals survival limits of kidney transplantation in older and high-risk patients
2025-06-04
(Vienna, Austria, Thursday 5 June 2025) A major international study, being presented today at the 62nd ERA Congress, reveals that the long-accepted survival advantage of deceased-donor kidney transplantation does not extend equally to every patient and every donor organ.1,2
A large-scale analysis, drawing on data from the European Renal Association (ERA) Registry, examined five-year survival outcomes in 64,013 wait-listed adults across Catalonia, Denmark, France, Norway, and the UK who began dialysis between 2000 and 2019. Using a robust target trial emulation (TTE) framework designed to mirror ...
Targeting mitochondria to fight leukemia: Rice University-led research team pursues new treatment strategies
2025-06-04
Acute myeloid leukemia (AML) remains one of the most aggressive and deadly forms of blood cancer, even as treatments have advanced in recent years. Standard approaches like high-dose chemotherapy and bone marrow transplants can extend life but often come at the cost of severe side effects — and many patients still relapse due to drug-resistant cancer cells.
A research team led by Natasha Kirienko at Rice University is working to change that by turning the cancer cells’ own energy ...
Antibiotics taken during pregnancy may reduce preterm births
2025-06-04
A study of almost 1000 pregnant women in Zimbabwe found that a daily dose of a commonly used, safe and inexpensive antibiotic may have led to fewer babies being born early. Among women living with HIV, those who received the antibiotic had larger babies who were less likely to be preterm.
One in four live-born infants worldwide is preterm (born at 37 weeks’ gestation or before), is small for gestational age, or has a low birth weight. The mortality rate for these small and vulnerable newborns is high, with prematurity now the leading cause of death among ...
Vigilance and targeted public health measures are essential in the face of the diphtheria epidemic that has affected vulnerable populations in Western Europe since 2022
2025-06-04
A study published in the New England Journal of Medicine (NEJM) reveals that the largest diphtheria epidemic in Western Europe for 70 years, which broke out in 2022 among migrants and in 2023 spread to other vulnerable populations in several European countries, is the result of contaminations occurring during migratory travel or in destination European countries, and not in the countries of origin. However, the geographical area and conditions of these initial contaminations are still unknown. A genetic link has also been established between the strain that circulated during the 2022 epidemic and an epidemic that occurred in Germany in 2025, suggesting ...
New study: Personalized exercise boosts health for people with neuromuscular disease
2025-06-04
EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, JUNE 4, 2025
MINNEAPOLIS — While many people with neuromuscular diseases currently face a future without a cure, a new study finds that a personalized exercise and coaching program could improve their fitness and overall health. The study is published on June 4, 2025, online in Neurology®, the medical journal of the American Academy of Neurology.
The study looked at people with a variety of neuromuscular diseases that cause muscle weakness and loss, including ...
FAMU-FSU College of Engineering researchers discover universal law of quantum vortex dynamics
2025-06-04
An international research collaboration featuring scientists from the FAMU-FSU College of Engineering and the National High Magnetic Field Laboratory discovered a fundamental universal principle that governs how microscopic whirlpools interact, collide and transform within quantum fluids, which also has implications for understanding fluids that behave according to classical physics.
The study, which was published in the Proceedings of the National Academy of Sciences, revealed new insights into vortex dynamics ...
AI analysis of ancient handwriting provides new age estimates for Dead Sea Scrolls
2025-06-04
An AI program trained to study the handwriting styles of centuries-old manuscripts from the Middle East suggests that many of the Dead Sea Scrolls might be older than previously thought, according to a study published June 4, 2025 in the open-access journal PLOS One by Mladen Popović from the University of Groningen, The Netherlands, and colleagues. This method could give researchers a new way to place undated manuscripts into the timeline of ancient history.
While some ancient manuscripts have dates written on them, giving archaeologists a precise understanding of when they ...
As many as 1 in 5 women with a history of pregnancy or testing for pregnancy report using crisis pregnancy centers across 4 US states
2025-06-04
Between 12 and 20% of women with a history of pregnancy or testing for pregnancy visited crisis pregnancy centers across four U.S. states, according to a new study by Maria Gallo and colleagues from The Ohio State University, U.S., published June 4, 2025, in the open-access journal PLOS One.
Crisis pregnancy centers (CPCs) typically provide pregnancy and parenting resources and associate with organizations which promote missions focused on preventing abortion, opposing contraception, and advocating for abstinence outside of marriage. They are typically not medically licensed clinics, though they can be perceived as medical facilities or abortion clinics, and often provide ...
LAST 30 PRESS RELEASES:
Hyperspectral sensor pushes weed science a wave further
War, trade and agriculture spread rice disease across Africa
Study identifies a potential treatment for obesity-linked breathing disorder
From single cells to complex creatures: New study points to origins of animal multicellularity
Language disparities in continuous glucose monitoring for type 2 diabetes
New hormonal pathway links oxytocin to insulin secretion in the pancreas
Optimal management of erosive esophagitis: An evidence-based and pragmatic approach
For patients with multiple cancers, a colorectal cancer diagnosis could be lifesaving — or life-threatening
Digital inhalers may detect early warning signs of COPD flare-ups
Living near harmful algal blooms reduces life expectancy with ALS
Chemical analysis of polyphenolic content and antioxidant screening of 17 African propolis samples using RP-HPLC and spectroscopy
Mount Sinai and Cancer Research Institute team up to improve patient outcomes in immunotherapy
Suicide risk elevated among young adults with disabilities
Safeguarding Mendelian randomization: editorial urges rethink in methodological rigor
Using AI to find persuasive public health messages and automate real-time campaigns
Gene therapy for glaucoma
Teaching robots to build without blueprints
Negative perception of scientists working on AI
How disrupted daily rhythms can affect adolescent brain development
New use for old drug: study finds potential of heart drug for treating growth disorders
Head-to-head study shows bariatric surgery superior to GLP-1 drugs for weight loss
Psychiatric disorders less likely after weight-loss surgery than treatment with GLP-1s
The higher the body mass index, the higher the risk for complications after bariatric surgery
Black patients have higher rate of minor complications after metabolic and bariatric surgery than white patients
A revolution for R&D with the missing link of machine learning — project envisions human-AI expert teams to solve grand challenges
4 ERC Advanced Grants: 10 million Euro for ISTA
ERC awards €2.5 million to TIGEM scientist for project on programmable genetic circuits
Tree rings reveal increasing rainfall seasonality in the Amazon
Scientists find unexpected deep roots in plants
Researchers unveil the immune cells responsible for systemic sclerosis’s deadliest complications
[Press-News.org] Diabetes drug shows benefits for patients with liver diseaseResults support the potential for dapagliflozin to benefit these patients